Novartis AG (SWX:NOVN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 190.49B |
| Revenue (ttm) | 43.89B |
| Net Income (ttm) | 10.86B |
| Shares Out | 1.94B |
| EPS (ttm) | 5.45 |
| PE Ratio | 18.06 |
| Forward PE | 14.27 |
| Dividend | 3.50 (3.56%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 2,204,321 |
| Average Volume | 2,600,034 |
| Open | 98.30 |
| Previous Close | 98.40 |
| Day's Range | 98.08 - 99.37 |
| 52-Week Range | 81.10 - 104.62 |
| Beta | 0.56 |
| RSI | 50.67 |
| Earnings Date | Oct 28, 2025 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial numbers in USD Financial StatementsNews
Novartis to Launch Direct-to-Patient Platform for Cosentyx in U.S.
The company is the latest pharma giant to move on price-cutting ahead of the Trump administration's deadline.
Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US
Basel, September 29, 2025 – Today, Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 1, 2025, offering cash-paying patients prescr...
Novartis announces commencement of tender offer to acquire Tourmaline Bio
Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer...
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
Basel, September 26, 2025 – Novartis will present new data from 34 abstracts across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin (October 17-21, 2...
DFIV, B, TD, NVS: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Dimensional International Value ETF (Symbol: DFIV) where we have detec...
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
Basel, September 24, 2025 – Novartis today announced new data from two Kesimpta® (ofatumumab) studies in relapsing multiple sclerosis (RMS) that will be presented at the European Committee for Treatme...
A Nobel Prize? How Big Pharma is trying to appease Trump
Novartis' CEO said his company was working with the US 'on eliminating the price gap between the US and other industrialised countries'
Novartis Builds US Drug Reserves Against Potential Tariffs
Novartis AG (NYSE: NVS) has reportedly built up its pharmaceutical stockpiles in the U.S. as a cushion against the potential impact of tariffs under consideration by the Trump administration, chief e...
Novartis (NVS) Boosts U.S. Pharmaceutical Inventory Amid Tariff Concerns
Novartis (NVS) Boosts U.S. Pharmaceutical Inventory Amid Tariff Concerns
Novartis (NVS) CEO Discusses Potential U.S. Price Reductions
Novartis (NVS) CEO Discusses Potential U.S. Price Reductions
Novartis ramps up US stockpiles to shield against potential tariffs
Novartis AG (NOVN.S) has significantly increased its stockpiles of pharmaceuticals in the United States and is positioning itself to withstand potential tariffs, Chief Executive Officer Vas Narasimhan...
Novartis (NVS) Evaluates U.S. Drug Pricing Amid Government Pressure
Novartis (NVS) Evaluates U.S. Drug Pricing Amid Government Pressure
Novartis (NVS) Plans Price Reduction Proposal for U.S. Market
Novartis (NVS) Plans Price Reduction Proposal for U.S. Market
Novartis CEO reportedly weighing U.S. price cuts as Trump’s MFN deadline nears
Novartis has stockpiles to withstand potential Trump tariffs, CEO says
Novartis has increased its stockpiles of pharmaceuticals in the United States and is well prepared should its products be hit by President Donald Trump's tariffs, its chief executive said in an interv...
Irelands pharma sector is world class, but why dont we have a Novo Nordisk to take our success to the next level?
Denmark has Novo Nordisk, France has Sanofi, Switzerland boasts both Roche and Novartis, while Germany has Bayer. Its a somewhat troubled relationship, but Britain has AstraZeneca.
AVDE, NVS, UBS, TM: ETF Inflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Avantis International Equity ETF (Symbol: AVDE) where we have detected...
Who benefits if NHS drug prices soar? Donald Trump and big pharma. Just one more way he’s menacing Britain | Polly Toynbee
The NHS needs cheap drugs, and our economy needs a thriving pharma industry. The president threatens both – no wonder Labour is grovelling to him Governing in the era of Donald Trump has been Labour’s...
Monte Rosa Therapeutics (GLUE) Soars on Novartis Collaboration
Monte Rosa Therapeutics (GLUE) Soars on Novartis Collaboration
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments
Monte Rosa Therapeutics Inc . (NASDAQ: GLUE) stock is surging on Monday, with a session volume of 11.67 million compared to the average volume of 408.08 thousand as per data from Benzinga Pro . Monte...
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments
Monte Rosa Therapeutics Inc. GLUE stock is surging on Monday, with a session volume of 11.67 million compared to the average volume of 408.08 thousand as per data from Benzinga Pro.
Monte Rosa stock rises after pact with Novartis
Novartis (NVS) and Monte Rosa Partner to Advance Immune Disease Treatments
Novartis (NVS) and Monte Rosa Partner to Advance Immune Disease Treatments
Novartis signs up to US$5.7 billion licensing deal with Monte Rosa Therapeutics
Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to US$5.7 billion on Monday to develop drugs for immune-mediated diseases.
Novartis, Monte Rosa strike $5.7 billion drug development deal
Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases.